LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

CytoSorbents Corp

Cerrado

SectorSanidad

0.76 -5

Resumen

Variación precio

24h

Actual

Mínimo

0.76

Máximo

0.79

Métricas clave

By Trading Economics

Ingresos

-5.1M

-3.2M

Ventas

-132K

9.5M

BPA

-0.05

Margen de beneficios

-33.421

Empleados

149

EBITDA

-5.9M

-2.9M

Dividendos

By Dow Jones

Próximas Ganancias

11 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.8M

47M

Apertura anterior

5.76

Cierre anterior

0.76

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

CytoSorbents Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 mar 2026, 19:32 UTC

Adquisiciones, fusiones, absorciones

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mar 2026, 22:26 UTC

Noticias de Eventos Importantes

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Charlas de Mercado

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Ganancias

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Noticias de Eventos Importantes

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Ganancias

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Ganancias

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Ganancias

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Noticias de Eventos Importantes

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Charlas de Mercado

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Charlas de Mercado
Noticias de Eventos Importantes

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Charlas de Mercado

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Ganancias

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Ganancias

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Ganancias

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Charlas de Mercado

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar 2026, 17:46 UTC

Noticias de Eventos Importantes

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar 2026, 17:40 UTC

Charlas de Mercado
Ganancias

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar 2026, 17:40 UTC

Ganancias

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 17:32 UTC

Charlas de Mercado
Noticias de Eventos Importantes

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar 2026, 17:28 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar 2026, 17:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

6 mar 2026, 17:20 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

6 mar 2026, 17:20 UTC

Adquisiciones, fusiones, absorciones

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Comparación entre iguales

Cambio de precio

CytoSorbents Corp previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.705 / 0.771Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

154 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.